4 Needs context
A person who reaches age 85 in the United States has about a 40% chance of being diagnosed with Alzheimer's disease.
"And statistically, if you live to be age 85, you've got about a 40% chance in America of being actually diagnosed with that pathological state, the most powerful risk factor for which is your chronological age." (said at 0:08:41)
Epidemiological estimates in the United States indicate that chronological age is the strongest risk factor for Alzheimer's disease, and the prevalence of Alzheimer's dementia among individuals aged 85 and older is estimated at approximately one-third (around 33% to 40% depending on the cohort and diagnostic criteria). Describing this as an individual's "40% chance of being diagnosed" roughly aligns with population prevalence estimates for the oldest-old (age 85+), though actual clinical diagnosis rates are somewhat lower due to widespread underdiagnosis.
In 24 species, including humans, lifespan is tied to the rate of telomere shortening.
"In 24 species, including humans, lifespans are tied to that shortening." (said at 0:10:05)
Comparative studies examining telomere dynamics across diverse animal species and humans have shown that the rate of telomere shortening, rather than initial telomere length alone, strongly correlates with species lifespan. For example, Whittemore et al. (2019) measured longitudinal telomere shortening rates across various bird and mammalian species alongside human data, concluding that telomere shortening rate predicts species maximum lifespan. The claim captures the core scientific finding that species longevity correlates with telomere shortening rates, though the exact number of species and the causal universality across all taxa remain subjects of ongoing debate in evolutionary biology.
Certain LRRK2 gene variants linked to increased Parkinson's disease risk impair the formation of microtubules used to transfer mitochondria between cells.
"And that uh one of the um LRRK variants that uh is associated with increased risk of Parkinson's for example is a failure to form those microtubules." (said at 0:37:15)
Preclinical in vitro research demonstrates that the common Parkinson's disease-associated mutation LRRK2 G2019S impairs intercellular mitochondrial transfer (such as from astrocytes to dopaminergic neurons) and alters cytoskeletal and mitochondrial dynamics. However, this mechanism has been demonstrated in cellular and induced pluripotent stem cell (iPSC) models rather than directly in clinical trials or human patients in vivo, and intercellular mitochondrial transfer relies on multifactorial mechanisms including Drp1-STX17 signaling and tunneling nanotube dynamics.
An adenovirus gene therapy trial shut down the field of gene therapy in 1990 due to an adverse event.
"adenovirus which is a large virus and and it is the one that kind of shut down gene therapy in in 1990 due to an ill effect." (said at 0:39:44)
The claim is partially accurate regarding the cause and impact of the adverse event, but contains a significant error regarding the date. The landmark adenovirus gene therapy trial that caused severe immunotoxicity, resulted in a high-profile patient death, and halted/slowed clinical gene therapy research occurred in September 1999 (the trial for ornithine transcarbamylase deficiency led by the University of Pennsylvania, in which 18-year-old Jesse Gelsinger died), not in 1990. In 1990, the first approved human gene therapy trial took place (using a retroviral vector for adenosine deaminase deficiency in a four-year-old patient), which was successful and safe.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.